|
distant sites
The problem seems that assessing the status, either HER2, E or P, seems to by the one treatment limiting factor. When asked at SABCS, Dr. Sleaman stated that when ever a biopsy of distant metastatic sites is done, either by fine needle aspiration or core needle biopsie (the most common) there is always the posibility of spread, however remote. I must wonder if the Bayer test, or a variation of it, for serum HER2 cells might be a future way of assessing the change in HER2 status. I may e-mail Bayer for feed-back, as a possible future direct. I think that this is a HUGH issue given the fact that a very large percentage of stage 4'ers may be under-treated.
Al
__________________
Primary care-giver to and advocate for Linda, who passed away April 27, 2006.
|